Apellis Pharmaceuticals 미래 성장

Future 기준 확인 5/6

Apellis Pharmaceuticals (는) 각각 연간 64.2% 및 16.4% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 66% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 56.5% 로 예상됩니다.

주요 정보

64.2%

수익 성장률

65.97%

EPS 성장률

Biotechs 수익 성장	23.6%
매출 성장률	16.4%
향후 자기자본 수익률	56.52%
애널리스트 커버리지	Good
마지막 업데이트	30 May 2025

최근 미래 성장 업데이트

Recent updates

Apellis Pharmaceuticals: Have Some Patience

May 20

Analysts Just Slashed Their Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) EPS Numbers

May 09

SYFOVRE And EMPAVELI Will Broaden Treatment Options Globally

May 02 SYFOVRE's strategic expansion and dominant GA market role could significantly drive revenue growth and international market penetration.

The Market Doesn't Like What It Sees From Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) Revenues Yet As Shares Tumble 26%

Apr 11

There's No Escaping Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) Muted Revenues Despite A 26% Share Price Rise

Dec 15

Would Apellis Pharmaceuticals (NASDAQ:APLS) Be Better Off With Less Debt?

Oct 18

Apellis Pharmaceuticals: Assessing The Impact Of The Negative CHMP Opinion

Oct 01

Investors Aren't Buying Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) Revenues

Sep 27

Apellis: Rare Kidney Disease Data Leads To Possible First To Market

Aug 09

Health Check: How Prudently Does Apellis Pharmaceuticals (NASDAQ:APLS) Use Debt?

Jul 12

What Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) P/S Is Not Telling You

May 30

It's Probably Less Likely That Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) CEO Will See A Huge Pay Rise This Year

May 30

Apellis Pharmaceuticals Strives For Recovery Despite Syfovre Setbacks

May 14

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 09

Apellis Pharmaceuticals: Eye Disease Drug Syfovre On Comeback Trail - But Risks Remain

Feb 16

With A 55% Price Drop For Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) You'll Still Get What You Pay For

Jul 19

Analysts Are Betting On Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) With A Big Upgrade This Week

May 13

Is Apellis Pharmaceuticals (NASDAQ:APLS) Using Debt In A Risky Way?

Apr 18

수익 및 매출 성장 예측

NasdaqGS:APLS - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2027	1,221	173	55	97	18
12/31/2026	962	-56	-61	-26	21
12/31/2025	776	-236	-119	-131	20
3/31/2025	776	-224	-8	-8	N/A
12/31/2024	781	-198	-88	-88	N/A
9/30/2024	715	-250	-206	-205	N/A
6/30/2024	629	-333	-409	-408	N/A
3/31/2024	524	-417	-551	-550	N/A
12/31/2023	397	-529	-596	-595	N/A
9/30/2023	273	-606	-639	-638	N/A
6/30/2023	185	-657	-625	-623	N/A
3/31/2023	106	-691	-582	-580	N/A
12/31/2022	75	-652	-515	-514	N/A
9/30/2022	113	-634	-486	-485	N/A
6/30/2022	97	-638	-501	-500	N/A
3/31/2022	81	-702	-522	-521	N/A
12/31/2021	67	-746	-564	-563	N/A
9/30/2021	256	-520	-310	-309	N/A
6/30/2021	251	-460	-245	-240	N/A
3/31/2021	251	-360	-211	-205	N/A
12/31/2020	251	-345	-166	-160	N/A
9/30/2020	1	-536	-389	-385	N/A
6/30/2020	N/A	-470	-340	-338	N/A
3/31/2020	N/A	-423	-285	-284	N/A
12/31/2019	N/A	-305	-213	-211	N/A
9/30/2019	N/A	-228	-175	-174	N/A
6/30/2019	N/A	-194	-154	-153	N/A
3/31/2019	N/A	-156	-145	-144	N/A
12/31/2018	N/A	-128	N/A	-131	N/A
9/30/2018	N/A	-109	N/A	-102	N/A
6/30/2018	N/A	-85	N/A	-80	N/A
3/31/2018	N/A	-64	N/A	-61	N/A
12/31/2017	N/A	-51	N/A	-47	N/A
9/30/2017	N/A	-39	N/A	-38	N/A
6/30/2017	N/A	-35	N/A	-33	N/A
3/31/2017	N/A	-30	N/A	-28	N/A
12/31/2016	N/A	-27	N/A	-26	N/A
9/30/2016	N/A	-29	N/A	-27	N/A
6/30/2016	N/A	-53	N/A	-24	N/A
3/31/2016	N/A	-50	N/A	-21	N/A
12/31/2015	N/A	-47	N/A	-19	N/A
9/30/2015	N/A	-41	N/A	-14	N/A
6/30/2015	N/A	-12	N/A	-14	N/A
3/31/2015	N/A	-12	N/A	-12	N/A

애널리스트 미래 성장 예측

수입 대 저축률: APLS 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률( 2.9% )보다 빠른 성장으로 간주됩니다.

수익 vs 시장: APLS (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.

고성장 수익: APLS 향후 3년 내에 수익을 낼 것으로 예상됩니다.

수익 대 시장: APLS 의 수익(연간 16.4% ) US 시장( 8.5% 보다 빠르게 성장할 것으로 예상됩니다. 8.5% 연간).

고성장 수익: APLS 의 수익(연간 16.4% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: APLS 의 자본 수익률은 3년 내에 매우 높을 것으로 예상됩니다( 56.5 %).

성장 기업 발견

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2025/06/01 17:29
장 마감 주가	2025/05/30 00:00
수익	2025/03/31
연간 수익	2024/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처는 미국 증권의 예를 사용했습니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 Github에서 확인할 수 있습니다.

애널리스트 출처

Apellis Pharmaceuticals, Inc. 34 애널리스트 중 21 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Colleen Kusy	Baird
Michael Ulz	Baird
Ishan Majumdar	Baptista Research

Apellis Pharmaceuticals 미래 성장

Future 기준 확인 5/6

주요 정보

최근 미래 성장 업데이트

Consensus EPS estimates fall by 81%

Price target decreased by 7.3% to US$39.05

Forecast breakeven date pushed back to 2027

Forecast breakeven date moved forward to 2026

Consensus EPS estimates fall by 24%

Price target decreased by 18% to US$51.79

Recent updates

Apellis Pharmaceuticals: Have Some Patience

Consensus EPS estimates fall by 81%

Price target decreased by 7.3% to US$39.05

Analysts Just Slashed Their Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) EPS Numbers

Forecast breakeven date pushed back to 2027

First quarter 2025 earnings: EPS and revenues miss analyst expectations

SYFOVRE And EMPAVELI Will Broaden Treatment Options Globally

Apellis Pharmaceuticals, Inc., Annual General Meeting, Jun 03, 2025

Apellis Pharmaceuticals, Inc Announces Craig Wheeler to Join the Board of Directors, Effective April 21, 2025

The Market Doesn't Like What It Sees From Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) Revenues Yet As Shares Tumble 26%

Apellis Pharmaceuticals, Inc. Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for Empaveli (pegcetacoplan) for C3G and Primary IC-MPGN

Apellis Pharmaceuticals (NASDAQ:APLS) Is Making Moderate Use Of Debt

Apellis Pharmaceuticals: A Mixed Bag

Forecast breakeven date moved forward to 2026

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Apellis Pharmaceuticals, Inc. and Sobi Announces EMA Validation of Indication Extension Application for Aspaveli®? (Pegcetacoplan) for C3g and Primary Ic-Mpgn

Apellis Receives Approval of SYFOVRE (pegcetacoplan) in Australia for Geographic Atrophy (GA)

Co-Founder recently sold US$412k worth of stock

Co-Founder notifies of intention to sell stock

Apellis Pharmaceuticals, Inc. Announces Executive Changes

New minor risk - Insider selling

Apellis Pharmaceuticals Appoints Keli Walbert to the Board of Directors

Apellis: Saved By The October Data

There's No Escaping Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) Muted Revenues Despite A 26% Share Price Rise

Consensus EPS estimates fall by 24%

Price target decreased by 18% to US$51.79

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Sobi and Apellis Pharmaceuticals, Inc. Announces Detailed Data from the Phase 3 Valiant Study

Apellis Pharmaceuticals, Inc. Presents Positive Results from the Phase 3 VALIANT Study at Kidney Week

Price target decreased by 7.0% to US$63.11

Would Apellis Pharmaceuticals (NASDAQ:APLS) Be Better Off With Less Debt?

Forecast breakeven date pushed back to 2026

Apellis Pharmaceuticals: Assessing The Impact Of The Negative CHMP Opinion

Investors Aren't Buying Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) Revenues

Apellis: Rare Kidney Disease Data Leads To Possible First To Market

Sobi and Apellis Announce Positive Topline Results from Phase 3 Valiant Study of Pegcetacoplan in C3G and Primary IC-MPGN

Price target decreased by 7.6% to US$69.12

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates fall by 11%

Health Check: How Prudently Does Apellis Pharmaceuticals (NASDAQ:APLS) Use Debt?

Independent Director notifies of intention to sell stock

What Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) P/S Is Not Telling You

It's Probably Less Likely That Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) CEO Will See A Huge Pay Rise This Year

Apellis Pharmaceuticals, Inc. Announces Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress

Consensus EPS estimates fall by 17%

Apellis Pharmaceuticals Strives For Recovery Despite Syfovre Setbacks

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 18%

Apellis Pharmaceuticals, Inc., Annual General Meeting, Jun 05, 2024

Apellis Announces Pegcetacoplan MAA Review Reset to Initial Assessment by European Medicines Agency

Consensus EPS estimates upgraded to US$0.98 loss

Consensus EPS estimates upgraded to US$1.00 loss

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Chief Technical Operations Officer recently sold US$646k worth of stock

Apellis Pharmaceuticals, Inc. Announces Appointment of Philip Ferrone, M.D as Chief Medical Retina Advisor, Effective March 18, 2024

Consensus EPS estimates fall by 13%, revenue upgraded

Co-Founder notifies of intention to sell stock

New minor risk - Financial position

Apellis Pharmaceuticals: Eye Disease Drug Syfovre On Comeback Trail - But Risks Remain

Apellis Pharmaceuticals, Inc. Announces Negative CHMP Opinion for Pegcetacoplan for Ga in the European Union and Plans to Seek Re-Examination of Application

Co-Founder notifies of intention to sell stock

Apellis Pharmaceuticals, Inc. Appoints Adam Townsend as Chief Operating Officer

Co-Founder recently sold US$525k worth of stock

Price target increased by 9.0% to US$71.44

Price target decreased by 9.6% to US$66.69

Apellis Pharmaceuticals, Inc. Provides Update on Ongoing Regulatory Review of Pegcetacoplan for GA in the European Union